Skip to content
Search AI Powered

Latest Stories

Novartis scraps UK heart attack prevention trial

Novartis is halting a UK-based trial originally planned as part of a partnership with NHS England, a setback in its quest to win wider approval for its novel cholesterol-lowering drug to prevent heart attacks and strokes.

A spokesperson said that among the factors influencing the decision, the coronavirus pandemic had made it difficult to make progress on the trial.


Under the ORION-17 trial, planned to involve 40,000 patients, Novartis was trying to show that its Leqvio drug could prevent the first occurrence of major cardiovascular health problems in high-cholesterol patients, part of a broader collaboration with the British health system.

"After careful evaluation, we have decided not to move forward with ORION-17," the Swiss drugmaker said in an emailed statement on Wednesday. "We continue to have very high ambitions for Leqvio."

The drug is approved to prevent renewed cardiovascular crises like a heart attack or stroke in people who have already suffered one, known as secondary prevention.

Novartis said it would pursue a different global trial with 14,000 volunteers to show Leqvio's potential in primary prevention in people at high risk of suffering a first cardiovascular event.

Leqvio, a twice-a-year injection, has had a slow ramp-up phase because cardiologists need to be persuaded to change their billing routines, but analysts have predicted a more than $2 billion sales opportunity from 2025. It would be among the company's biggest growth drivers during that time.

Credit Suisse analysts said the withdrawal likely "reflects slow progress in initial UK roll out to (general practitioners) in secondary prevention".

In 2021, Novartis said it had agreed a deal with Britain's healthcare service provider over the use of Leqvio, after the country's healthcare cost agency NICE approved the medicine.

The NHS said its wider "population health agreement" with Novartis, which covers secondary prevention, remains in place, adding it "is a pioneering approach to improving treatment for eligible patients with cardiovascular disease across the country."

The Financial Times first reported that the trial would end.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
It is official: Opella is now a standalone company

Opella launches as an independent company to redefine the future of self-care.

Photo credit: gettyimages

Opella becomes standalone company as Sanofi-CD&R deal closes

Opella has officially become a standalone company, following the completion of Sanofi’s sale of a controlling 50.0% stake to private equity firm Clayton, Dubilier & Rice (CD&R).

Sanofi retains a significant shareholding with a 48.2% stake while Bpifrance holds the remaining 1.8% stake.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less